Breaking News, Collaborations & Alliances

Thermo Fisher, JW Therapeutics Form CAR-T Partnership in China

Companies join forces in cell therapy applications and commercial-scale manufacturing.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Thermo Fisher Scientific has signed an agreement with cell therapy company JW Therapeutics to ensure non-exclusive commercial access to Thermo Fisher’s Gibco CTS Dynabeads CD3/CD28.   The agreement will support the clinical development and commercial manufacturing of leading CAR-T (Chimeric Antigen Receptor T-Cells) therapies in China, including JW Therapeutics’ lead product relmacabtagene autoleucel (relma-cel). Relma-cel is an anti-CD19 CAR-T therapy for third-line treatment for re...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters